Clinical Trials

60 enrolled

Prostatic Neoplasms

NCT07103018 2026-03-16

STRIKE-001

144 enrolled

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

75 enrolled

Prostatic Neoplasms

NCT06463457 2026-03-09

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

33 enrolled

Prostatic Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

10 enrolled

Prostatic Neoplasms

NCT04736199 2026-02-27

ARANOTE

Phase 3 Completed

669 enrolled 16 charts

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

9 enrolled

Prostatic Neoplasms

NCT05997615 2026-02-24

AMX-500

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07406282 2026-02-12

Double-DARE

Recruiting

1,400 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT06627530 2026-02-11

COAction

144 enrolled

Prostatic Neoplasms

NCT05059236 2026-02-09

ARASEC

223 enrolled

Prostatic Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

30 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT05348876 2026-01-30

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Phase 4 Recruiting

50 enrolled

Prostatic Neoplasms

NCT07344779 2026-01-26

ROAD

Not yet recruiting

1,600 enrolled

Prostatic Neoplasms

NCT06120491 2026-01-21

EvoPAR-PR01

Phase 3 Recruiting

1,800 enrolled

Prostatic Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT05519449 2026-01-20

ENGAGER-PSMA-01

272 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06592924 2026-01-14

TRIPLE-SWITCH

Phase 3 Recruiting

830 enrolled

Phase 4 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

80 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

234 enrolled

Prostatic Neoplasms

NCT07282197 2025-12-15

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

40 enrolled

Prostatic Neoplasms

NCT07181122 2025-11-24

PRO-MIND

Recruiting

102 enrolled

Depression, Fatigue, Sleep Initiation and Maintenance Disorders, Prostatic Neoplasms

NCT04335682 2025-11-04

ARACOG

111 enrolled

Prostatic Neoplasms

NCT02972060 2025-09-19

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

61 enrolled

Prostatic Neoplasms

NCT07172685 2025-09-15

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Phase NA Recruiting

116 enrolled

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

200 enrolled

Prostatic Neoplasms

NCT04319783 2025-08-21

DECREASE

65 enrolled

Prostatic Neoplasms

NCT05202301 2025-08-11

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Completed

13,779 enrolled

Prostatic Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

250 enrolled

Prostatic Neoplasms

NCT05171387 2025-06-22

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

Phase 2 Completed

78 enrolled

Prostatic Neoplasms

NCT07027124 2025-06-18

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

40 enrolled

Prostatic Neoplasms

NCT04925648 2025-05-15

PICASSO

22 enrolled

Prostatic Neoplasms

NCT06190899 2025-03-21

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

54 enrolled

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT06652607 2025-03-12

PSA-DEEP02

Recruiting

152 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04070209 2024-12-04

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

66 enrolled

Prostatic Neoplasms

NCT06575257 2024-08-28

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

80 enrolled

Prostatic Neoplasms

NCT06435702 2024-05-30

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

Not yet recruiting

108 enrolled

Prostatic Neoplasms

NCT06430411 2024-05-28

OLIGOMET

Not yet recruiting

500 enrolled

Prostatic Neoplasms

NCT02933801 2024-03-13

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Phase 2 Terminated

92 enrolled

Prostatic Neoplasms

NCT05116475 2024-03-12

ALADDIN

Phase 3 Recruiting

152 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04641078 2024-02-28

DART

Phase 2 Unknown

124 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06282588 2024-02-28

THUNDER

Phase 2/3 Recruiting

493 enrolled

Prostatic Neoplasms

NCT04176081 2024-01-24

SChLAP/IDC

208 enrolled

BreastGenitourinary

Carcinoma, Intraductal, Noninfiltrating, Prostatic Neoplasms

NCT04737109 2023-11-13

ADDItion

Phase 1/2 Terminated

6 enrolled 9 charts

Prostatic Neoplasms

NCT05771896 2023-09-14

CARE

Phase 3 Withdrawn

Prostatic Neoplasms

NCT05900973 2023-08-07

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

Phase 2 Unknown

19 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04136353 2023-07-28

DASL-HiCaP

1,100 enrolled